Eli Lilly and Co (XSGO:LLYCL)
CLP 767490 -8430 (-1.09%) Market Cap: 728.77 Tn Enterprise Value: 755.05 Tn PE Ratio: 86.20 PB Ratio: 50.39 GF Score: 64/100

Eli Lilly and Co at Cowen Healthcare Conference (Virtual) Transcript

Mar 04, 2021 / 02:10PM GMT
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good morning and welcome to the Eli Lilly's session of Cowen's 41st Annual Healthcare Conference. We're very pleased to have with us today, Dr. Dan Skovronsky, who is Senior Vice President and Chief Scientific Officer.

Cowen has been recommending Lilly's stock now since 2014, and it has been a great stock because great companies tend to be great stocks. And great companies are led by great leaders. And we have one of those great leaders here today. So Dan, thank you for your time.

Daniel M. Skovronsky
Eli Lilly and Company - Senior VP, Chief Scientific Officer & President of Lilly Research Labs

Thank you, Steve.

Questions & Answers

Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Maybe we could start out by talking about tirzepatide because of the data that was just issued this morning, the SURPASS-2 data. Maybe you could just take a moment to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot